Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  NASDAQ OMX COPENHAGEN  >  BioPorto A/S    BIOPOR   DK0011048619

BIOPORTO A/S (BIOPOR)

 SummaryQuotesChartsNewsCalendarCompany 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq Omx Copenhagen
03/22/2017 03/23/2017 03/24/2017 03/27/2017 03/28/2017 Date
2.43(c) 2.41(c) 2.41(c) 2.44(c) 2.41(c) Last
261 824 175 360 221 742 100 637 60 611 Volume
-1.22% -0.82% 0.00% +1.24% -1.23% Change
More quotes
Company
BioPorto A/S is an in-vitro diagnostics company.It provides healthcare professionals in clinical and research settings a range of diagnostic tests and antibodies.The company focuses on the diagnosis of obesity, diabetes, primary immune deficiency, and kidney injury.Its products include The NGAL... 
Sector
Pharmaceuticals
Calendar
04/21Shareholder meeting
More about the company
Latest news on BIOPORTO A/S
03/17 BIOPORTO A/S : Notice Convening the Annual General Meeting
03/15 BIOPORTO A/S : Comeback with a view to growth.
02/09 BIOPORTO A/S : Announcement from major shareholder
02/03 BIOPORTO A/S : Siemens cooperation enters into the next phase.
02/02 BIOPORTO A/S : Siemens cooperation enters into the next phase.
01/30 BIOPORTO A/S : completes pre-submission discussions with the FDA
2016 BIOPORTO A/S : expands its NGAL related patent portfolio
2016 BIOPORTO A/S : BioPortos gRAD platform validated for QIAGENs ESEQuant lateral fl..
2016 BIOPORTO A/S : gRAD platform validated for QIAGEN’s ESEQuant lateral flow ..
2016 BIOPORTO A/S : Financial Calendar 2017
More news
Sector news : Diagnostic & Testing Substances Manufacturers
03/28DJSenator McCaskill Begins Probe of Prescription Opioid Marketing -- 2nd Update
03/28DJSHIRE : Files 8K - Other Events
03/28DJSenator McCaskill Begins Probe of Prescription Opioid Marketing -- Update
03/28DJSenator McCaskill Begins Probe of Prescription Opioid Marketing
03/28DJREGENERON PHARMACEUTICALS : FDA Approves Regeneron and Sanofi's Dupixent for Ecz..
More sector news : Diagnostic & Testing Substances Manufacturers
Latest Tweets
01/30BioPorto A/S: BioPorto completes pre-submission discussions with the FDA #Fin.. 
2016BioPorto A/S: BioPorto expands its NGAL related patent portfolio #Finanzierun.. 
2016Nasdaq Copenhagen A/S: BioPorto A/S - admittance to trading and official list.. 
More tweets
Qtime:2
Advertisement
Chart BIOPORTO A/S
Duration : Period :
BioPorto A/S Technical Analysis Chart | BIOPOR | DK0011048619 | 4-Traders
Full-screen chart
Technical analysis trends BIOPORTO A/S
Short TermMid-TermLong Term
TrendsBearishBullishNeutral
Technical analysis
Managers
NameTitle
Peter Mørch Eriksen CEO & Investor Relations Contact
Thomas Magnussen Chairman
Jan Kuhlmann Andersen Chief Operating Officer
Jakob Brix Christensen Chief Financial Officer
Torben A. Nielsen Vice Chairman
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
BIOPORTO A/S14.76%0
JOHNSON & JOHNSON8.91%341 030
ROCHE HOLDING LTD.8.73%220 248
PFIZER INC.5.23%203 546
NOVARTIS AG-0.47%195 735
MERCK & CO., INC.7.34%173 493
More Results